Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy: The POSEIDON Randomized Trial

Study Questions:

How safe are allogeneic mesenchymal stem cells (MSCs), compared to autologous MSCs, for treatment of patients with left ventricular (LV) dysfunction due to ischemic cardiomyopathy (ICM)?